Daniel Weber, DO
Epilepsy · Saint Louis, MONPI 1215166814
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $41,300 of the $48,692 with a category attached, or 84.8%. SK Life Science, Inc. accounts for 94.1% of it on its own, with 12 other manufacturers making up the rest. Reporting peaked in 2022 at $22,036 and has fallen 95.1% since, to $1,070 in 2025. Among epilepsy clinicians in MO with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 162 payments — averaging $300.57 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- SK Life Science, Inc.$46K
- UCB, Inc.$1K
- Jazz Pharmaceuticals Inc.$670
- Greenwich Biosciences, Inc.$278
- Neurelis, Inc.$273
- Boston Scientific$143
- plus $462 from 7 others
Across 4 payments — averaging $3466.34 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Medtronic$14K
What the payments were for
- Speaking & faculty fees$41,30085%
- Travel & lodging$1,4613%
- Food & beverage$5,74612%
- Education$1850%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| SK Life Science, Inc. | 61 | $45,817 |
| UCB, Inc. | 50 | $1,050 |
| Jazz Pharmaceuticals Inc. | 23 | $670 |
| Greenwich Biosciences, Inc. | 12 | $278 |
| Neurelis, Inc. | 3 | $273 |
| Boston Scientific | 1 | $143 |
| Sunovion Pharmaceuticals Inc. | 3 | $118 |
| Sanofi | 1 | $111 |
| Medtronic(2 entities) | 2 | $66 |
| Neuropace, Inc. | 1 | $63 |
| Eisai Inc. | 2 | $45 |
| Geistlich Pharma, North America, Inc. | 1 | $29 |
| Livanova USA, Inc. | 2 | $28 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- XCOPRI$36,886
- Cenobamate$6,450
- Epidiolex$369
- VALTOCO$162
- GENERAL DBS$143
- NEXVIAZYME$111
How this compares
$48,692 in reported general payments places this provider in the 95th percentile of 26 epilepsy providers in Missouri.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| XcopriCenobamate | 103 | $177,668 |
| AptiomEslicarbazepine Acetate | 59 | $128,512 |
| BriviactBrivaracetam | 50 | $79,949 |
| EpidiolexCannabidiol (Cbd) | 35 | $76,482 |
| FycompaPerampanel | 33 | $42,384 |
| NayzilamMidazolam | 32 | $22,220 |
| Lacosamide | 183 | $21,760 |
| VimpatLacosamide | 21 | $19,472 |
| Levetiracetam | 254 | $14,395 |
| Clobazam | 65 | $13,095 |
| Oxcarbazepine | 103 | $8,145 |
| Carbamazepine ErCarbamazepine | 79 | $6,472 |
| Lamotrigine ErLamotrigine | 12 | $4,781 |
| Zonisamide | 104 | $4,717 |
| Divalproex Sodium ErDivalproex Sodium | 51 | $4,527 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| SK Life Science, Inc.Xcopri | $45,817 | $177,668103 claims |
| Sunovion Pharmaceuticals Inc.Aptiom | $118 | $128,51259 claims |
| UCB, Inc.Briviact, Nayzilam, Vimpat | $1,050 | $121,641103 claims |
| Eisai Inc.Fycompa | $45 | $42,38433 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 26 epilepsy providers in Missouri.
Other epilepsy in Saint Louis
- Robert HoganSaint Louis$13K
- Renee ShellhaasSaint Louis$12K
- Fabio Nascimento E SilvaSaint Louis$11K
- Oleg LobanovSaint Louis$7K
- Thomas FoutzSaint Louis$4K
- Adam GreenblattSaint Louis$3K
- Robin RytherSaint Louis$2K
- Jonathan WilliamsSaint Louis$1K
- Michael WongSaint Louis$1K
- Saumel AhmadiSaint Louis$789
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.